Miglustat Dipharma

Miglustat, the active ingredient in Miglustat Dipharma, is a glucosylceramide synthase inhibitor presented as an oral tablet for oral use. It treats Gaucher disease type 1 and Niemann‑Pick disease type C in appropriate patients.

GNH USA supplies Miglustat Dipharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Miglustat is used as substrate reduction therapy for lysosomal storage disorders, targeting glycosphingolipid synthesis. - Gaucher disease type 1: reduces accumulation of glucocerebroside, improving hematologic and organ manifestations. - Niemann‑Pick disease type C: decreases glycosphingolipid synthesis, supporting neurological and systemic symptom management. - Lysosomal storage disorders: provides substrate reduction therapy for applicable conditions.

Miglustat may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: loose stools often occurring early in therapy. - Nausea: feeling of sickness or upset stomach. - Weight loss: unintended reduction in body weight. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas requiring immediate medical attention. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes indicating potential liver injury.

Before prescribing Miglustat, clinicians should consider several safety aspects. - Renal function: monitor creatinine clearance in patients with kidney disease. - Liver function: assess hepatic enzymes before initiating therapy. - Pregnancy: safety not established; avoid use unless benefits outweigh risks. - Concomitant medications: evaluate potential interactions with oral antidiabetics. - Patient counseling: advise on possible gastrointestinal upset and importance of adherence. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Miglustat can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce miglustat exposure, compromising efficacy. - Concurrent use with high‑dose oral antidiabetics: can increase risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours. - Warfarin: may require INR monitoring due to potential effect on coagulation. - Contraceptive steroids: may have altered plasma levels; monitor effectiveness.